Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT07228208
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Endothelial Dysfunction
  • Type 2 Diabetes (T2DM)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • MitoQ (mitoquinol mesylate) — DIETARY_SUPPLEMENT
    During each testing session, the investigators will be measuring how one treatment of an over-the-counter antioxidant supplement affects blood flow and muscle function. One day participants will orally ingest an over-the-counter antioxidant supplement called MitoQ.
  • Placebo — DIETARY_SUPPLEMENT
    During each testing session, the investigators will be measuring how one treatment of an over-the-counter antioxidant supplement affects blood flow and muscle function. One day participants will orally ingest an over-the-counter antioxidant supplement called MitoQ, while the other they will ingest a placebo

Study Details

Exaggerated blood pressure responses to exercise in individuals with Type 2 Diabetes significantly increase the risk of heart attack, stroke, and cardiovascular death, while also limiting exercise capacity and therapeutic benefits of physical activity. This research will determine whether impaired blood vessel function and excessive cellular damage from oxygen-containing molecules cause these dangerous blood pressure responses during exercise. The findings will establish whether targeting cellular antioxidant systems represents a new therapeutic approach to improve exercise tolerance and reduce cardiovascular risk in t Americans living with diabetes.

Key Dates

Start date
Sep 1, 2026
Status verified
Sep 2025
Primary completion
Jun 30, 2031
Completion
Dec 31, 2031

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Antioxidant Supplementation
    MitoQ, a mitochondrial target antioxidant, given once at a dose of 160 mg
  • Placebo Comparator: Placebo
    A placebo similar visually will be used to compare to MitoQ

Primary Outcome Measure

Mean Arterial Pressure [ Time Frame: Prior to and 45 minutes following supplement ]

Locations (1)

FacilityCityStateZIPSite coordinators
Medical College of WisconsinMilwaukeeWisconsin53226
William E Hughes, Ph.D.
[email protected]

Find similar trials in Milwaukee, WI

By research site
Medical College of Wisconsin· Milwaukee, WI

Related Studies